CoChat

Impaired peripheral glucose homeostasis and Alzheimer's disease

Wijesekara, Nadeeja, Gonçalves, Rafaella Araujo, De Felice, Fernanda G., Fraser, Paul E. · 2018 · Neuropharmacology
Cited by 80

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Abstract

Alzheimer's disease (AD) is the most common type of dementia. Recent studies suggest that metabolic disturbances, particularly type 2 diabetes (T2D) increase the risk of cognitive decline and AD. AD is also a risk factor for T2D, and a growing body of evidence indicates that these diseases are connected both at clinical and molecular levels. In T2D, peripheral insulin resistance, hyperglycemia and eventually insulin deficiency develops, leading to an overall decline in tissue health. More recently, brain insulin resistance has been shown to be a key feature of AD that is linked to neuronal dysfunction and cognitive impairment. Furthermore, both AD and T2D are amyloidogenic diseases, with abnormal aggregation of amyloid‐&bgr; peptide (A&bgr;) and islet amyloid polypeptide (IAPP) respectively contributing to cellular death and disease pathogenesis. Emerging data suggests that A&bgr; may have peripheral effects including its co‐deposition in the pancreas. In this review, we discuss how peripheral effects of A&bgr; and metabolic disturbances may impact AD pathogenesis. This article is part of the Special Issue entitled ‘Metabolic Impairment as Risk Factors for Neurodegenerative Disorders.’ HighlightsAlzheimer's disease and type 2 diabetes present a significant risk to each other.The two diseases are mechanistically linked by amyloidogenesis, insulin resistance, oxidative stress and inflammation.Combined effects of A&bgr; and IAPP amyloid deposition in brain and periphery exacerbate both disease phenotypes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.neuropharm.2017.11.027

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 44 references

Cited by

See all 80

Metadata

Authors
Wijesekara, N., Gonçalves, R. A., De Felice, F. G., & Fraser, P. E.
Venue
Neuropharmacology
Publisher
Elsevier BV
Published
2018-07
Volume
136
Issue
Pt B
Pages
172-181
ISSN
0028-3908 (ISSN-L)
OpenAlex
W2770969431
Cited by
80
References
44
FWCI
6.01
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impaired peripheral glucose homeostasis and Alzheimer's disease. https://app.cochat.ai/papers/10.1016/j.neuropharm.2017.11.027
The paper
Wijesekara, N., Gonçalves, R. A., De Felice, F. G., & Fraser, P. E. (2018). Impaired peripheral glucose homeostasis and Alzheimer's disease. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2017.11.027

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.